We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
VelociSuite technologies facilitate rapid generation of optimized antibodies allowing for cell line production and large-scale bioreactor manufacturing.
Kodiak's lead asset is designed to have a longer half-life than other anti-VEGF drugs. The hope is to improve patient adherence to a treatment that is injected into the eyes.